<font> NeoStem, Inc. </font> (AMEX:NBS)is a pioneer and leader in the pre-disease collection, processing and long-term storage of adult stem cells for the general population to use in future medical applications. The Company's business model includes generating revenue through ongoing fees associated with a minimally invasive, proprietary stem cell collection process, in addition to fees charged to the centers for marketing and long-term storage.
NeoStem targets its marketing efforts toward health conscious consumers to encourage them to donate and store their stem cells as a form of bio-insurance for possible use in later years or to address an emerging medical need.
Pro-Active Research Group initiated coverage of NeoStem on 5/27/09 with a speculative buy rating and $5/share long-term price target. The PDF report is available to view or download for free at the
<font> BioMedReports.com stock research </font> reports section.
Disclosure: No positions.
$2.3 (06/19/09)
